ReviewImmunologic research2015
T regulatory cells: Achilles' heel of Mycobacterium tuberculosis infection?
Review in Immunologic research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- Classification and characterisation of extracellular vesicles-related tuberculosis subgroups and immune cell profiles.Journal of cellular and molecular medicine · 2023Article
- Molecular Markers of Early Immune Response in Tuberculosis: Prospects of Application in Predictive Medicine.International journal of molecular sciences · 2023Review
- Preclinical Evaluation of TB/FLU-04L-An Intranasal Influenza Vector-Based Boost Vaccine against Tuberculosis.International journal of molecular sciences · 2023Article
- Relationship between Vitamin D and Immunity in Older People with COVID-19.International journal of environmental research and public health · 2023Review
- Molecular and Cellular Mechanisms ofInternational journal of molecular sciences · 2022Review
- The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic.Frontiers in immunology · 2022Review
- Increase of CD4+CD25highFoxP3+ cells impairs in vitro human microbicidal activity against Mycobacterium tuberculosis during latent and acute pulmonary tuberculosis.PLoS neglected tropical diseases · 2021Article
- The Role of Dendritic Cells in TB and HIV Infection.Journal of clinical medicine · 2020Review
- BCG: a vaccine with multiple faces.Human vaccines & immunotherapeutics · 2020Review
- Non-tuberculous, adenosine deaminase-positive lymphocytic pleural effusion: Consider immunoglobulin G4-related disease.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2020Article
- TLR1/2 orchestrate human plasmacytoid predendritic cell response to gram+ bacteria.PLoS biology · 2019Article
- Immune Response toFrontiers in pediatrics · 2019Review
- The role of T regulatory cell-associated markers in monitoring tuberculosis treatment completion and failure.Immunologic research · 2018Article
- Limited Foxp3Frontiers in immunology · 2018Article
- Frequency of Circulating CD4Frontiers in immunology · 2018Article
- Efficacy of T Regulatory Cells, Th17 Cells and the Associated Markers in Monitoring Tuberculosis Treatment Response.Frontiers in immunology · 2018Article
- Proteomics ofFrontiers in immunology · 2018Review
- New Genome-Wide Algorithm Identifies Novel In-Vivo Expressed Mycobacterium Tuberculosis Antigens Inducing Human T-Cell Responses with Classical and Unconventional Cytokine Profiles.Scientific reports · 2016Article
- Vitamin D and Lung Infection.Infection and immunity · 2016Article
- Assessment of treatment response in tuberculosis.Expert review of respiratory medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T regulatory cells (Treg) constitute a specialized subset of T cells that play a pivotal role in preventing the occurrence of autoimmune diseases by suppressing deleterious activities of immune cells. Contrarily, they can have adverse effect on immune response against infectious diseases where Treg weaken the host immunity leading to enhanced microbial load and thereby increase in severity of the disease. Here, we have attempted to review plethora of information documenting prevalence of Treg in tuberculosis (TB) and their involvement in progression and immunopathogenesis of the disease. Further, we have laid emphasis on the possible use of Treg as a biomarker for determining the TB treatment efficacy. Also, we have discussed the probable contribution of Treg in dampening the efficacy of BCG, the anti-TB vaccine. Finally, we have speculated some of the possible strategies which might be explored by exploiting Treg for enhancing the efficacy of TB management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.